Inadequate or inappropriate treatment is currently seen in 20–25% of septic patients and is associated with a five-fold reduction in survival.1
The National Nosocomial Infection Surveillance System reports that sepsis is the leading cause of death in non-coronary ICUs, with the cost of care exceeding $17 billion in the US annually.2
Identification of bloodstream pathogens using traditional culture methods alone requires up to 3 days, with antimicrobial resistance mechanisms requiring additional testing after a bacterial isolate is obtained. Patients are often treated with broad, empiric antimicrobial therapy until a final ID and sensitivity is reported, contributing to increased antimicrobial resistance, hospital costs, and lengths of stay3.
Non-pathogenic blood culture contaminants from the patient’s skin or the environment frequently result in unnecessary hospital stays and antimicrobial therapy.
Finally, as more payers are pushing back on extensive “one-size-fits-all” diagnostic panels, clinicians are looking for testing solutions that make sense based on gram stain results.
Provide actionable information to clinicians to direct appropriate therapy sooner. Great Basin’s Staph ID/R Blood Culture Panel offers exceptional ease of use, which means staff on any shift can run the panel. Further, it delivers results in about 90 minutes, meaning that patients with likely contaminants or methicillin susceptible pathogens can be de-escalated without waiting for the final culture ID and sensitivity.
Report results with confidence. Great Basin’s Staph ID/R Blood Culture Panel is the only diagnostic panel to include our patented amplification suppressor technology that completely blocks detection of contaminants present in the environment that may lead to a false positive result and potential misdiagnosis of a patient. The technology distinguishes between Staphylococcus species present in a clinical sample from low-level Staphylococcus contamination that is introduced during the sample collection or testing process that does not contribute to “bottle ring,” while not negatively impacting the appropriate clinical assay limit of detection, which means the Staph ID/R Blood Culture Panel provides the sensitivity and specificity you would expect from a molecular assay, but with unparalleled ease of use.
Avoid unnecessary cost with a right-sized panel. Cost-effectively test for the pathogens that make sense based on the gram stain results. Great Basin’s Staph ID/R Blood Culture Panel identifies the following directly from positive blood cultures found to contain gram-positive cocci in clusters or singles:
- Staphylococcus aureus (MRSA or MSSA)
- Staphylococcus lugdunensis (typically the only CoNS that is considered a true pathogen)
- OTHER Staphylococcus species (without identification to the species level)
- Mixed infections of S. aureus and S. lugdunensis with OTHER Staphylococcus species
- mecA gene (confers methicillin resistance)
Want more information?
For more information on the Great Basin Staph ID/R Blood Culture Panel, or to purchase our system, please contact us.
1Lebovitz EE, Burbelo PD. Commercial Multiplex Technologies for the Microbiological Diagnosis of Sepsis. Molecular diagnosis & therapy. 2013;17(4):221-231. doi:10.1007/s40291-013-0037-4.
2National Surveillance Infections Surveillance (NNIS) System Report (Jan 1992-June 2004). Am. J. Infect. Control 2004; Oct; 32:470-485.
3Klevens RM, Morrison, MA, Nadle J, et.al. “Invasive Methicillin-Resistant Staphylococcus aureusInfections in the United States.” JAMA 2007; Oct 17; 298(15):1763-1771.